UPCOMING SESSIONS in ET
Wed, Apr 8, 2026
10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next Heather Landau Click To Register
UPCOMING SESSIONS in ET
Wed, Apr 8, 2026 · 10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next
Heather Landau
Click To Register
View all sessions

Chemotherapy

Feb 29, 2020
Light-chain (AL) amyloidosis is a systemic syndrome characterized by progressive organ dysfunction leading to organ failure and death. The heart is the most…
Jan 27, 2020
Background/Aims: The present Bayesian network meta-analysis (NMA) was to compare the efficacy of different chemotherapies and autologous stem cell transplantation (…
Dec 25, 2016
Systemic light-chain (AL) amyloidosis is an infiltrative disorder associated with an underlying plasma cells dyscrasia, in which monoclonal immunoglobulin light…
Oct 21, 2015
Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the…
Sep 14, 2015
Amyloidosis is a disease in which proteins misfold, aggregate into fibrils, and deposit extracellularly disrupting organ architecture and function. There are two…
Aug 19, 2015
Systemic AL amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly but treatment and outcomes have not been…
In February 2014, Sondra Kunes was feeling a little more fatigued than usual, but wrote it off as being 54 and raising five children ranging from their early teens…
Doctors are working to learn more about amyloidosis, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this…